Monday 6-9-2014 Merrimack Pharmaceuticals Inc (MAC
Post# of 72
Posted On: 06/09/2014 6:33:39 PM
Monday 6-9-2014 Merrimack Pharmaceuticals Inc (MACK) $MACK opened at 7.67 hitting the high price of 7.97 and a day low of 7.66 with a total volume of 1,196,153. MACK had a previous close of 7.67 and has been seeing an average volume of 1,861,998.
Overall Average: 80% Buy
Recent stock forum discussions about MACK http://investorshangout.com/search?q=MACK&...mp;yt0=Go!
3 Reasons Why Wall Street Hates Merrimack Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Thu Jun 05, 12:43PM CDT
A rising short interest is often times a bad omen for a stock. Specifically, the high degree of risk involved in shorting tends to ensure that short-sellers have a clear cut investing thesis for why a particular stock is overvalued. Merrimack... (full story)
Merrimack Pharmaceuticals Presents Phase 1 Clinical Data Supporting Four Novel Antibody Therapeutic Programs at the 2014 ASCO Annual Meeting
GlobeNewswire - Mon Jun 02, 3:00PM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Phase 1 clinical data from studies of MM-151, MM-141, MM-111 and MM-121 was presented at the 2014 American Society of Cancer Oncology (ASCO) Annual Meeting. Data from these studies support the clinical advancement of Merrimack's novel antibody therapeutics. (full story)
Merrimack Pharmaceuticals Identifies Heregulin as Patient Response Biomarker for MM-121 and Standard of Care Therapy Across Multiple Cancers
GlobeNewswire - Mon Jun 02, 8:35AM CDT
Studies indicate that 30-50 percent of patients most at risk of progression may benefit from MM-121 (full story)
Brain Cancer - Pipeline Review, H1 2014: 19 Companies Profiled
M2 - Thu May 29, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hqsqp9/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope: - The report provides a snapshot of the global therapeutic landscape of Brain Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Brain Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - AngioChem Inc. - Basilea Pharmaceutica AG - Bionomics Limited - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals. LLC - DEKK-TEC, Inc. - EGEN, Inc. - Immune Pharmaceuticals, Inc. - Kinex Pharmaceuticals, LLC - Merrimack Pharmaceuticals, Inc. - Neuralstem, Inc. - Nuvilex, Inc. - Oncology Research International Limited - Prana Biotechnology Limited - Stemline Therapeutics, Inc. - TAU Therapeutics, LLC - TVAX Biomedical, Inc. - e-Therapeutics plc - to-BBB technologies BV For more information visit http://www.researchandmarkets.com/research/hq...ain_cancer (full story)
Fundraising Support, Upcoming Conferences, Clinical Data Presentations, and Cash Dividends - Analyst Notes on WellCare, NPS Pharma, Merrimack Pharmaceuticals, CONMED and Haemonetics
PR Newswire - Wed May 28, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding WellCare Health Plans, Inc. (NYSE: WCG), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Merrimack Pharmaceuticals Inc (NASDAQ: MACK), CONMED Corporation (NASDAQ: CNMD) and Haemonetics Corporation (NYSE: HAE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3014-100free. (full story)
Equities Marking a New High -- Research on JD.com, NRG Energy, Merrimack Pharma and Arris Group
PR Newswire - Wed May 28, 4:40AM CDT
The U.S. markets on Tuesday, May 27, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,675.50, up 0.42% and the NASDAQ Composite closed at 4,237.07, up 1.22%. The S&P 500 finished the session 0.60% higher at 1,911.91. During the trading session, nine out of ten sectors finished on a higher note. Investor-Edge looks at some of the equities that hit a new 52-week high during the last session. These include JD.com Inc. (NASDAQ: JD), NRG Energy Inc. (NYSE: NRG), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) and Arris Group Inc. (NASDAQ: ARRS). Free technical research on JD, NRG, MACK and ARRS can be downloaded upon signing up at: (full story)
Merrimack Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference
GlobeNewswire - Tue May 27, 7:00AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President & CEO, is scheduled to present at the Jefferies 2014 Global Healthcare Conference on Tuesday, June 3, 2014 at 4:00 p.m. (ET) in New York City. (full story)
Merrimack Pharmaceuticals to Present Clinical Data Across Oncology Pipeline at ASCO 2014
GlobeNewswire - Thu May 22, 6:37PM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced it will present clinical data on four novel antibody cancer therapeutics at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, May 30-June 3, 2014 at McCormick Place in Chicago. These presentations showcase Merrimack's broad oncology pipeline. (full story)
Global Squamous Cell Carcinoma Therapeutics Pipeline Review 2014
M2 - Tue May 20, 9:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/72tfpz/squamous_cell) has announced the addition of the "Squamous Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Squamous Cell Carcinoma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Squamous Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Squamous Cell Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - Novartis AG - Genmab A/S - Celgene Corporation - Clinuvel Pharmaceuticals Limited - Oncolytics Biotech Inc. - Oryzon Genomics S.A. - Hutchison MediPharma Limited - Merrimack Pharmaceuticals, Inc. - Neotropix, Inc. - Axelar AB - Onconova Therapeutics, Inc. - Omeros Corporation - Cellceutix Corporation - Cannabis Science, Inc. - Oncovir, Inc. - Genextra S.p.a. - Bexion Pharmaceuticals, LLC. - AbbVie Inc. Drug Profiles - afatinib - paclitaxel albumin-bound - AXL-1717 - pelareorep - rigosertib sodium - afamelanotide - boanmycin hydrochloride [docetaxel] - CIGB-128 - DAC-0060 - Poly-ICLC - BYL-719 - LJM-716 - interleukin-15 - Antibody Drug Conjugate for Squamous Cell Tumor - irinotecan sucrosofate liposomal - Kevetrin - CUV-9900 - BXQ-350 - CS-TATI-1 - CS-S/BCC-1 - TF-011-Monomethyl Auristatin E - AMXT-1501 eflornithine - Allogenic Mesenchymal Stem Cells - HMPL-453 - NTX-500 - GPR87 Antagonist for Cancer - GPR39 Antagonist for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes - Monoclonal Antibody For Squamous Cell Cancer - Drugs for Cutaneous Squamous Cell Carcinoma (cSCC) For more information visit http://www.researchandmarkets.com/research/72...amous_cell (full story)
Merrimack Pharma and the Marginal Benefit of Pancreatic Cancer Drug MM-398
at The Street - Wed May 14, 6:00AM CDT
The commercial potential of MM-398 is not entirely clear, despite the positive pancreatic cancer trial and an FDA approval that will likely come from it. (full story)
5 Stocks Ready for Breakouts
at The Street - Fri May 09, 1:41PM CDT
These stocks look ready to break out and trade higher from current levels. (full story)
Should You Buy Merrimack Pharmaceuticals (MACK) Ahead of Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 09, 7:45AM CDT
Merrimack Pharmaceuticals has been witnessing a significant price rise in the past month with a positive momentum in the earnings estimate front (full story)
Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack
at The Street - Fri May 09, 5:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies. (full story)
Jim Cramer's 'Mad Money' Recap: Bubbles vs. Valuation
at The Street - Thu May 08, 7:22PM CDT
Unlike the dot-com bubble, new companies today can make a profit but choose not to do so, prefering high valuations, Cramer says. (full story)
Merrimack Pharmaceuticals to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
GlobeNewswire - Wed May 07, 3:47PM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Ulrik Nielsen, Chief Scientific Officer, is scheduled to present at the Bank of America Merrill Lynch 2014 Health Care Conference on Wednesday, May 14, 2014 at 3:00 p.m. (PT) at the Encore at the Wynn in Las Vegas. (full story)
Neuroblastoma Pipeline Review 2014: 32 Companies & 73 Drug profiles
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9pzz2k/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Neuroblastoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neuroblastoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Neuroblastoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - United Therapeutics Corporation - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Novartis AG - Chugai Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Progenics Pharmaceuticals, Inc. - Celgene Corporation - AEterna Zentaris Inc. - Lixte Biotechnology Holdings, Inc. - Lorus Therapeutics Inc. - Novogen Limited - Threshold Pharmaceuticals, Inc. - Sareum Holdings plc - MabVax Therapeutics, Inc. - Bionucleon Srl - CerRx, Inc. - Merrimack Pharmaceuticals, Inc. - Neotropix, Inc. - APEIRON Biologics AG - Xcovery, Inc. - Sutro Biopharma, Inc. - Incuron, LLC - Errant Gene Therapeutics, LLC - DEKK-TEC, Inc. - Bexion Pharmaceuticals, LLC. - Cancer Prevention Pharmaceuticals, Inc. - CureFAKtor Pharmaceuticals. LLC For more information visit http://www.researchandmarkets.com/research/9p...roblastoma (full story)
Biotech Stock Roundup: Endocyte Tumbles & Merrimack Soars on Pipeline News - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed May 07, 8:34AM CDT
Several companies reported earnings and provided regulatory and pipeline updates last week. (full story)
Nuvilex's Pancreatic Cancer Treatment Continues to Outperform Big Pharma Heading Into Late Phase Trials
Marketwire - Wed May 07, 8:04AM CDT
Nuvilex, Inc.'s (OTCQB: NVLX) advanced pancreatic cancer treatment first outperformed historical data presented by the NYSE's Eli Lilly and its FDA approved pancreatic cancer drug Gemzar(R), then it was NASDAQ's Celgene and its recently FDA approved treatment of Abraxane(R) plus gemcitabine, and now the latest treatment that Nuvilex's Cell-in-a-Box(R) combined with the anticancer drug ifosfamide outperforms is NASDAQ-listed Merrimack Pharmaceuticals and its treatment, the combination of MM-398 with 5-fluorouracil (5-FU) and leucovorin. (full story)
Biotech Stocks Review -- Research on Retrophin, Merrimack, Gilead Sciences, and Rexahn Pharma
PR Newswire - Tue May 06, 11:37AM CDT
The U.S. markets on Monday, May 5, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,530.55, up 0.11% and the NASDAQ Composite closed at 4,138.06, up 0.34%. The S&P 500 finished the session 0.19% higher at 1,884.66. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 672.57, up 0.56%, with the index advancing 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: Retrophin Inc. (NASDAQ: RTRX), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Gilead Sciences Inc. (NASDAQ: GILD) and Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN). Free technical research on RTRX, MACK, GILD and RNN can be downloaded upon signing up at: (full story)
The Feuerstein-Ratain Rule Update: Still Perfect Predicting Small-Cap Cancer Drug Failure
at The Street - Tue May 06, 9:00AM CDT
The F-R Rule is still 100% accurate predicting failure for oncology phase III studies undertaken by companies with market caps less than $300 million. (full story)
Overall Average: 80% Buy
Recent stock forum discussions about MACK http://investorshangout.com/search?q=MACK&...mp;yt0=Go!
3 Reasons Why Wall Street Hates Merrimack Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Thu Jun 05, 12:43PM CDT
A rising short interest is often times a bad omen for a stock. Specifically, the high degree of risk involved in shorting tends to ensure that short-sellers have a clear cut investing thesis for why a particular stock is overvalued. Merrimack... (full story)
Merrimack Pharmaceuticals Presents Phase 1 Clinical Data Supporting Four Novel Antibody Therapeutic Programs at the 2014 ASCO Annual Meeting
GlobeNewswire - Mon Jun 02, 3:00PM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Phase 1 clinical data from studies of MM-151, MM-141, MM-111 and MM-121 was presented at the 2014 American Society of Cancer Oncology (ASCO) Annual Meeting. Data from these studies support the clinical advancement of Merrimack's novel antibody therapeutics. (full story)
Merrimack Pharmaceuticals Identifies Heregulin as Patient Response Biomarker for MM-121 and Standard of Care Therapy Across Multiple Cancers
GlobeNewswire - Mon Jun 02, 8:35AM CDT
Studies indicate that 30-50 percent of patients most at risk of progression may benefit from MM-121 (full story)
Brain Cancer - Pipeline Review, H1 2014: 19 Companies Profiled
M2 - Thu May 29, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hqsqp9/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope: - The report provides a snapshot of the global therapeutic landscape of Brain Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Brain Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - AngioChem Inc. - Basilea Pharmaceutica AG - Bionomics Limited - Critical Outcome Technologies Inc. - CureFAKtor Pharmaceuticals. LLC - DEKK-TEC, Inc. - EGEN, Inc. - Immune Pharmaceuticals, Inc. - Kinex Pharmaceuticals, LLC - Merrimack Pharmaceuticals, Inc. - Neuralstem, Inc. - Nuvilex, Inc. - Oncology Research International Limited - Prana Biotechnology Limited - Stemline Therapeutics, Inc. - TAU Therapeutics, LLC - TVAX Biomedical, Inc. - e-Therapeutics plc - to-BBB technologies BV For more information visit http://www.researchandmarkets.com/research/hq...ain_cancer (full story)
Fundraising Support, Upcoming Conferences, Clinical Data Presentations, and Cash Dividends - Analyst Notes on WellCare, NPS Pharma, Merrimack Pharmaceuticals, CONMED and Haemonetics
PR Newswire - Wed May 28, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding WellCare Health Plans, Inc. (NYSE: WCG), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Merrimack Pharmaceuticals Inc (NASDAQ: MACK), CONMED Corporation (NASDAQ: CNMD) and Haemonetics Corporation (NYSE: HAE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3014-100free. (full story)
Equities Marking a New High -- Research on JD.com, NRG Energy, Merrimack Pharma and Arris Group
PR Newswire - Wed May 28, 4:40AM CDT
The U.S. markets on Tuesday, May 27, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,675.50, up 0.42% and the NASDAQ Composite closed at 4,237.07, up 1.22%. The S&P 500 finished the session 0.60% higher at 1,911.91. During the trading session, nine out of ten sectors finished on a higher note. Investor-Edge looks at some of the equities that hit a new 52-week high during the last session. These include JD.com Inc. (NASDAQ: JD), NRG Energy Inc. (NYSE: NRG), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) and Arris Group Inc. (NASDAQ: ARRS). Free technical research on JD, NRG, MACK and ARRS can be downloaded upon signing up at: (full story)
Merrimack Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference
GlobeNewswire - Tue May 27, 7:00AM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President & CEO, is scheduled to present at the Jefferies 2014 Global Healthcare Conference on Tuesday, June 3, 2014 at 4:00 p.m. (ET) in New York City. (full story)
Merrimack Pharmaceuticals to Present Clinical Data Across Oncology Pipeline at ASCO 2014
GlobeNewswire - Thu May 22, 6:37PM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced it will present clinical data on four novel antibody cancer therapeutics at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, May 30-June 3, 2014 at McCormick Place in Chicago. These presentations showcase Merrimack's broad oncology pipeline. (full story)
Global Squamous Cell Carcinoma Therapeutics Pipeline Review 2014
M2 - Tue May 20, 9:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/72tfpz/squamous_cell) has announced the addition of the "Squamous Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Squamous Cell Carcinoma and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Squamous Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Squamous Cell Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - Novartis AG - Genmab A/S - Celgene Corporation - Clinuvel Pharmaceuticals Limited - Oncolytics Biotech Inc. - Oryzon Genomics S.A. - Hutchison MediPharma Limited - Merrimack Pharmaceuticals, Inc. - Neotropix, Inc. - Axelar AB - Onconova Therapeutics, Inc. - Omeros Corporation - Cellceutix Corporation - Cannabis Science, Inc. - Oncovir, Inc. - Genextra S.p.a. - Bexion Pharmaceuticals, LLC. - AbbVie Inc. Drug Profiles - afatinib - paclitaxel albumin-bound - AXL-1717 - pelareorep - rigosertib sodium - afamelanotide - boanmycin hydrochloride [docetaxel] - CIGB-128 - DAC-0060 - Poly-ICLC - BYL-719 - LJM-716 - interleukin-15 - Antibody Drug Conjugate for Squamous Cell Tumor - irinotecan sucrosofate liposomal - Kevetrin - CUV-9900 - BXQ-350 - CS-TATI-1 - CS-S/BCC-1 - TF-011-Monomethyl Auristatin E - AMXT-1501 eflornithine - Allogenic Mesenchymal Stem Cells - HMPL-453 - NTX-500 - GPR87 Antagonist for Cancer - GPR39 Antagonist for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes - Monoclonal Antibody For Squamous Cell Cancer - Drugs for Cutaneous Squamous Cell Carcinoma (cSCC) For more information visit http://www.researchandmarkets.com/research/72...amous_cell (full story)
Merrimack Pharma and the Marginal Benefit of Pancreatic Cancer Drug MM-398
at The Street - Wed May 14, 6:00AM CDT
The commercial potential of MM-398 is not entirely clear, despite the positive pancreatic cancer trial and an FDA approval that will likely come from it. (full story)
5 Stocks Ready for Breakouts
at The Street - Fri May 09, 1:41PM CDT
These stocks look ready to break out and trade higher from current levels. (full story)
Should You Buy Merrimack Pharmaceuticals (MACK) Ahead of Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 09, 7:45AM CDT
Merrimack Pharmaceuticals has been witnessing a significant price rise in the past month with a positive momentum in the earnings estimate front (full story)
Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack
at The Street - Fri May 09, 5:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies. (full story)
Jim Cramer's 'Mad Money' Recap: Bubbles vs. Valuation
at The Street - Thu May 08, 7:22PM CDT
Unlike the dot-com bubble, new companies today can make a profit but choose not to do so, prefering high valuations, Cramer says. (full story)
Merrimack Pharmaceuticals to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
GlobeNewswire - Wed May 07, 3:47PM CDT
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Ulrik Nielsen, Chief Scientific Officer, is scheduled to present at the Bank of America Merrill Lynch 2014 Health Care Conference on Wednesday, May 14, 2014 at 3:00 p.m. (PT) at the Encore at the Wynn in Las Vegas. (full story)
Neuroblastoma Pipeline Review 2014: 32 Companies & 73 Drug profiles
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9pzz2k/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Neuroblastoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neuroblastoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Neuroblastoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - United Therapeutics Corporation - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Novartis AG - Chugai Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Progenics Pharmaceuticals, Inc. - Celgene Corporation - AEterna Zentaris Inc. - Lixte Biotechnology Holdings, Inc. - Lorus Therapeutics Inc. - Novogen Limited - Threshold Pharmaceuticals, Inc. - Sareum Holdings plc - MabVax Therapeutics, Inc. - Bionucleon Srl - CerRx, Inc. - Merrimack Pharmaceuticals, Inc. - Neotropix, Inc. - APEIRON Biologics AG - Xcovery, Inc. - Sutro Biopharma, Inc. - Incuron, LLC - Errant Gene Therapeutics, LLC - DEKK-TEC, Inc. - Bexion Pharmaceuticals, LLC. - Cancer Prevention Pharmaceuticals, Inc. - CureFAKtor Pharmaceuticals. LLC For more information visit http://www.researchandmarkets.com/research/9p...roblastoma (full story)
Biotech Stock Roundup: Endocyte Tumbles & Merrimack Soars on Pipeline News - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed May 07, 8:34AM CDT
Several companies reported earnings and provided regulatory and pipeline updates last week. (full story)
Nuvilex's Pancreatic Cancer Treatment Continues to Outperform Big Pharma Heading Into Late Phase Trials
Marketwire - Wed May 07, 8:04AM CDT
Nuvilex, Inc.'s (OTCQB: NVLX) advanced pancreatic cancer treatment first outperformed historical data presented by the NYSE's Eli Lilly and its FDA approved pancreatic cancer drug Gemzar(R), then it was NASDAQ's Celgene and its recently FDA approved treatment of Abraxane(R) plus gemcitabine, and now the latest treatment that Nuvilex's Cell-in-a-Box(R) combined with the anticancer drug ifosfamide outperforms is NASDAQ-listed Merrimack Pharmaceuticals and its treatment, the combination of MM-398 with 5-fluorouracil (5-FU) and leucovorin. (full story)
Biotech Stocks Review -- Research on Retrophin, Merrimack, Gilead Sciences, and Rexahn Pharma
PR Newswire - Tue May 06, 11:37AM CDT
The U.S. markets on Monday, May 5, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,530.55, up 0.11% and the NASDAQ Composite closed at 4,138.06, up 0.34%. The S&P 500 finished the session 0.19% higher at 1,884.66. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 672.57, up 0.56%, with the index advancing 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: Retrophin Inc. (NASDAQ: RTRX), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Gilead Sciences Inc. (NASDAQ: GILD) and Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN). Free technical research on RTRX, MACK, GILD and RNN can be downloaded upon signing up at: (full story)
The Feuerstein-Ratain Rule Update: Still Perfect Predicting Small-Cap Cancer Drug Failure
at The Street - Tue May 06, 9:00AM CDT
The F-R Rule is still 100% accurate predicting failure for oncology phase III studies undertaken by companies with market caps less than $300 million. (full story)
(0)
(0)Merrimack Pharmaceuticals Inc. (MACK) Stock Research Links
Scroll down for more posts ▼